Kalliolia Eirini, Silajdžić Edina, Nambron Rajasree, Costelloe Seán J, Martin Nicholas G, Hill Nathan R, Frost Chris, Watt Hilary C, Hindmarsh Peter, Björkqvist Maria, Warner Thomas T
Department of Clinical Neurosciences, UCL Institute of Neurology, London, United Kingdom.
Brain Disease Biomarker Unit, Department of Experimental Medical Science, Wallenberg Neuroscience Centre, Lund University, Lund, Sweden.
PLoS One. 2015 Oct 2;10(10):e0138848. doi: 10.1371/journal.pone.0138848. eCollection 2015.
Huntington's disease is an inherited neurodegenerative disorder characterised by motor, cognitive and psychiatric disturbances. Patients exhibit other symptoms including sleep and mood disturbances, muscle atrophy and weight loss which may be linked to hypothalamic pathology and dysfunction of hypothalamo-pituitary axes.
We studied neuroendocrine profiles of corticotropic, somatotropic and gonadotropic hypothalamo-pituitary axes hormones over a 24-hour period in controlled environment in 15 healthy controls, 14 premanifest and 13 stage II/III Huntington's disease subjects. We also quantified fasting levels of vasopressin, oestradiol, testosterone, dehydroepiandrosterone sulphate, thyroid stimulating hormone, free triiodothyronine, free total thyroxine, prolactin, adrenaline and noradrenaline. Somatotropic axis hormones, growth hormone releasing hormone, insulin-like growth factor-1 and insulin-like factor binding protein-3 were quantified at 06:00 (fasting), 15:00 and 23:00. A battery of clinical tests, including neurological rating and function scales were performed.
24-hour concentrations of adrenocorticotropic hormone, cortisol, luteinizing hormone and follicle-stimulating hormone did not differ significantly between the Huntington's disease group and controls. Daytime growth hormone secretion was similar in control and Huntington's disease subjects. Stage II/III Huntington's disease subjects had lower concentration of post-sleep growth hormone pulse and higher insulin-like growth factor-1:growth hormone ratio which did not reach significance. In Huntington's disease subjects, baseline levels of hypothalamo-pituitary axis hormones measured did not significantly differ from those of healthy controls.
The relatively small subject group means that the study may not detect subtle perturbations in hormone concentrations. A targeted study of the somatotropic axis in larger cohorts may be warranted. However, the lack of significant results despite many variables being tested does imply that the majority of them do not differ substantially between HD and controls.
亨廷顿舞蹈症是一种遗传性神经退行性疾病,其特征为运动、认知和精神障碍。患者还表现出其他症状,包括睡眠和情绪紊乱、肌肉萎缩和体重减轻,这些症状可能与下丘脑病变及下丘脑 - 垂体轴功能障碍有关。
我们在受控环境下,对15名健康对照者、14名症状前患者以及13名II/III期亨廷顿舞蹈症患者,在24小时内研究了促肾上腺皮质激素、生长激素和促性腺激素下丘脑 - 垂体轴激素的神经内分泌特征。我们还对加压素、雌二醇、睾酮、硫酸脱氢表雄酮、促甲状腺激素、游离三碘甲状腺原氨酸、游离总甲状腺素、催乳素、肾上腺素和去甲肾上腺素的空腹水平进行了定量分析。在06:00(空腹)、15:00和23:00对生长激素轴激素、生长激素释放激素、胰岛素样生长因子 -1和胰岛素样因子结合蛋白 -3进行了定量分析。进行了一系列临床测试,包括神经学评分和功能量表。
亨廷顿舞蹈症组与对照组之间,促肾上腺皮质激素、皮质醇、黄体生成素和卵泡刺激素的24小时浓度无显著差异。对照组和亨廷顿舞蹈症患者的白天生长激素分泌相似。II/III期亨廷顿舞蹈症患者睡眠后生长激素脉冲浓度较低,胰岛素样生长因子 -1:生长激素比值较高,但未达到显著水平。在亨廷顿舞蹈症患者中,所测量的下丘脑 - 垂体轴激素的基线水平与健康对照组无显著差异。
相对较小的受试者群体意味着该研究可能无法检测到激素浓度的细微变化。可能有必要对更大队列的生长激素轴进行针对性研究。然而,尽管测试了许多变量,但缺乏显著结果确实意味着其中大多数在亨廷顿舞蹈症患者和对照组之间没有实质性差异。